Saurashtra News

RNA pipeline constitutes 85+ key companies continuously working towards developing 100+ RNA treatment therapies, analyzes DelveInsight

 Breaking News
  • No posts were found

RNA pipeline constitutes 85+ key companies continuously working towards developing 100+ RNA treatment therapies, analyzes DelveInsight

March 13
21:32 2023
RNA pipeline constitutes 85+ key companies continuously working towards developing 100+ RNA treatment therapies, analyzes DelveInsight
RNA pipeline

DelveInsights, RNA Competitive landscape, 2023 report provides comprehensive insights about 85+ companies and 100+ RNA drugs in the RNA Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Ribonucleic acid (abbreviated RNA) is a nucleic acid present in all living cells that has structural similarities to DNA. Unlike DNA, however, RNA is most often single-stranded. An RNA molecule has a backbone made of alternating phosphate groups and the sugar ribose, rather than the deoxyribose found in DNA.  

 

To know more about the RNA Pipeline Analysis report, click here: RNA Competitive landscape

 

Key Takeaways from the RNA Competitive landscape report:

  • Leading RNA Companies working in the market are Alnylam Pharmaceuticals, Suzhou Ribo Life Sciences, Arrowhead Pharmaceuticals, Sylentis, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, Janssen Pharmaceuticals, Eli Lilly and Company, Dicerna Pharmaceuticals, Amgen, Sirnaomics, Silence Therapeutics, Sylentis, Aro Biotherapeutics and Others.
  • Key RNA therapies in various stages of development include Fitusiran, ARO-APOC3, LY3561774, DCR-HBVS, VIR-2218, Zilebesiran, OLX 101A and Others.
  • In November 2021, Arrowhead Pharmaceuticals announced that it entered into an exclusive license agreement with GSK under which GSK will develop and commercialize ARO-HSD.

 

DelveInsight’s RNA Report covers around 100+ products under different phases of clinical development like

  • Assessment by RNA Product Type
  • Assessment by Stage and Product Type of RNA
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration of RNA
  • Assessment by RNA Molecule Type
  • Assessment by Stage and Molecule Type of RNA

 

Emerging RNA Drugs Under Different Phases of Clinical Development Include:

Some of the RNA therapies are Vutrisiran, OLX 101A and Many Others.

 

Further RNA product details are provided in the report. Download the RNA Pipeline report to learn more about the emerging RNA therapies at: https://www.delveinsight.com/sample-request/rna-competitive-landscape

 

Key companies in the RNA Therapeutics Market:

Some of the RNA Companies working in the market are Alnylam Pharmaceuticals, Suzhou Ribo Life Sciences, Arrowhead Pharmaceuticals, Sylentis, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, Janssen Pharmaceuticals, Eli Lilly and Company, Dicerna Pharmaceuticals, Amgen, Sirnaomics, Silence Therapeutics, Sylentis, Aro Biotherapeutics and Others.

 

Request for Sample PDF Report to know in detail about the recent developments  and advancements in RNA clinical trials – Phases of RNA Drugs in Pipeline

 

Table of Content (TOC)

1. RNA Pipeline Report Introduction

2. RNA Pipeline Report Executive Summary

3. RNA Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. RNA Clinical Trial Therapeutics

6. RNA Pipeline: Late Stage Products (Pre-registration)

7. RNA Pipeline: Late Stage Products (Phase III)

8. RNA Pipeline: Mid Stage Products (Phase II)

9. RNA Pipeline: Early Stage Products (Phase I)

10. RNA Pipeline Therapeutic Assessment

11. Inactive Products in the RNA Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key RNA Companies

14. Key Products in the RNA Pipeline

15. Unmet Needs

16. RNA Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

 

Download Sample PDF Report to know more about @ RNA drugs and medication

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services